Massachusetts General Hospital: Prostatic Neoplasms trials

The registry lists 27 Prostatic Neoplasms studies with Massachusetts General Hospital as lead sponsor. 4 are open to participants now and 8 have results posted.

Phase 1 1Phase 2 9Phase 3 1No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Training on Systemic and Organ Spec. PM in PCNot yet recruitingNCT07768917Not applicable
• Flotufolastat F 18 PET in Men With Very Low PSA RecurrenceRecruitingNCT06862856
• Prostate Cancer Genetic Risk Evaluation and Screening StudyRecruitingNCT05129605
• Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing ProstatectomyRecruitingNCT01961713
• A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate CancerCompletedNCT02346526Phase 2Results posted
• Tivozanib + Enzalutamide in Adv Prostate CancerTerminatedNCT01885949Phase 2Results posted
• A Pilot Trial of Sonoelastography for Planning Tumor-targeted Prostate BiopsyTerminatedNCT01748890Not applicableResults posted
• Cabozantinib in Advanced Solid MalignanciesCompletedNCT01588821Phase 2Results posted
• Cabozantinib (XL184) in Men With Castrate-Resistant Prostate CancerCompletedNCT01347788Phase 1Results posted
• Metformin in Castration-Resistant Prostate CancerTerminatedNCT01215032Phase 2Results posted
• Study of SU11248 in Men With Advanced Prostate CancerCompletedNCT00299741Phase 2Results posted
• ET 743 (Yondelis) in Men With Advanced Prostate CancerCompletedNCT00147212Phase 2Results posted
• PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care InterventionCompletedNCT05755490Not applicable
• Validation of Software-based Fusion of Ultrasound and MRI Images of the ProstateCompletedNCT02882958
• Abiraterone Acetate for Castrate Resistant Prostate CancerCompletedNCT01961843Not applicable
• Shared Decision Making in Low Risk Prostate CancerWithdrawnNCT01673581
• Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate CancerActive, not recruitingNCT01617161Not applicable
• 11C Acetate Imaging Post ProstatectomyTerminatedNCT01602783Not applicable
• Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate CancerTerminatedNCT01226888
• Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer SurvivorsCompletedNCT00738140Phase 2
• Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate CancerStatus unknownNCT00681694
• Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate CancerCompletedNCT00456144
• Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate CancerCompletedNCT00455624
• Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate CancerCompletedNCT00182052Phase 3
• Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate CancerCompletedNCT00181584Phase 2
• Atrasentan and Zometa for Men With Prostate Cancer Metastatic to BoneCompletedNCT00181558Phase 2
• Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast CancerCompletedNCT00087347